📚 Part of the Diabetes Landmark Trials guide — every landmark trial in one place.
Series: Landmark Trials in Endocrinology & Metabolism | Study #22
Category: Type 2 Diabetes · Multifactorial Risk Reduction | Design: Single-centre, randomised controlled trial with observational follow-up | n: 160 | Follow-up: 13.3 years total (7.8-year RCT + 5.5-year observational)
📋 Summary
Authors: Gaede P, Lund-Andersen H, Parving HH, Pedersen O
Journal: N Engl J Med 2008;358:580–591 | DOI: 10.1056/NEJMoa0706245
The Steno-2 trial randomly assigned 160 patients with type 2 diabetes mellitus and persistent microalbuminuria at the Steno Diabetes Center in Copenhagen to either intensive multifactorial therapy or conventional multifactorial therapy. The intensive intervention targeted simultaneously tight glycaemic control (HbA1c below 6.5%), blood pressure below 130/80 mmHg, total cholesterol below 4.5 mmol/L, and triglycerides below 1.7 mmol/L, using ACE inhibitors (or angiotensin receptor blockers), statins, low-dose aspirin, and dietary and lifestyle counselling as a structured package. Conventional therapy followed national guidelines of the time. The mean treatment period was 7.8 years. Patients were subsequently followed observationally for a mean of 5.5 years until December 2006. The primary endpoint of this long-term analysis was time to death from any cause at 13.3 years of follow-up. Twenty-four patients in the intensive-therapy group died, compared with 40 in the conventional-therapy group (hazard ratio 0.54; 95% CI 0.32 to 0.89; p=0.02), a 46% relative reduction in all-cause mortality. Intensive therapy was also associated with lower risk of death from cardiovascular causes (HR 0.43; 0.19 to 0.94; p=0.04), cardiovascular events (HR 0.41; 0.25 to 0.67; p<0.001), progression to end-stage renal disease (1 vs 6 patients; p=0.04), and need for retinal photocoagulation (relative risk 0.45; p=0.02).
📊 Key Findings
| Outcome | Intensive | Conventional | Effect Size |
|---|---|---|---|
| All-cause mortality | 24 deaths | 40 deaths | HR 0.54 (0.32–0.89) · p=0.02 · 46% RRR |
| Cardiovascular death | — | — | HR 0.43 (0.19–0.94) · p=0.04 · 57% RRR |
| Cardiovascular events | — | — | HR 0.41 (0.25–0.67) · p<0.001 · 59% RRR |
| End-stage renal disease | 1 patient | 6 patients | p=0.04 |
| Retinal photocoagulation | — | — | RR 0.45 (0.23–0.86) · p=0.02 |
Steno-2
Landmark RCT · type 2 diabetes · 13.3 years
Simultaneously targeting glucose, blood pressure, lipids, and lifestyle cut all-cause mortality by 46% and cardiovascular events by 59% over 13.3 years in high-risk type 2 diabetes.
💬 Expert Commentary
Steno-2 is the definitive proof-of-concept trial for the multifactorial risk reduction approach that underpins modern type 2 diabetes management. Its contribution is conceptually distinct from the single-intervention trials that preceded it: rather than demonstrating the benefit of glucose, blood pressure, or lipid lowering in isolation, Steno-2 showed that simultaneously targeting all major cardiovascular risk factors in a structured, protocol-driven manner produces mortality reductions that far exceed what any single intervention has achieved in isolation. The 46% reduction in all-cause mortality and 57% reduction in cardiovascular death over 13.3 years in a group of only 160 patients is one of the most impressive therapeutic outcomes in the modern diabetes trial literature, and the effect size strongly suggests that the interventions are synergistic rather than merely additive. The absolute risk reduction translates to approximately 1 in 4 patients being prevented from dying over 13.3 years with intensive multifactorial management — an NNT of approximately 5 for mortality prevention.
The Steno-2 population was specifically selected for microalbuminuria, which serves as a marker of generalised cardiovascular risk in type 2 diabetes beyond its nephropathy significance. The intensive intervention package, which combined ACE inhibitor or ARB therapy, statin, aspirin, intensive glucose lowering, and structured dietary and physical activity counselling, is now standard of care for all patients with type 2 diabetes at elevated cardiovascular risk. The trial also demonstrated durable benefits in nephropathy and retinopathy progression, extending the protective effect across all three major complication categories. Steno-2 was the evidence basis for the statement in multiple guidelines that comprehensive cardiovascular risk management is more important than optimising any single risk factor in high-risk type 2 diabetes.
Limitations: The trial enrolled only 160 patients at a single specialist centre, limiting generalisability to populations managed in primary care or without specialist support. The multifactorial nature of the intervention makes it impossible to isolate the contribution of any single component. The observational follow-up phase introduces potential for confounding. The study was funded by Novo Nordisk and other industry partners.
🔑 BOTTOM LINE
Steno-2 demonstrated that intensive multifactorial risk factor intervention reduces all-cause mortality by 46% and cardiovascular events by 59% over 13.3 years in type 2 diabetes with microalbuminuria, providing the definitive evidence that simultaneous targeting of glycaemia, blood pressure, lipids, and lifestyle produces synergistic reductions in mortality and complications that exceed any single-factor intervention.
⭐ Clinical Impact Rating: ●●●●● Practice-defining